Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles

• Published in: International journal of nanomedicine Vol. 9; no. Issue 1; pp. 1833 - 1843
• Main Authors: Rodriguez-Gascon, Alicia, del Pozo-Rodriguez, Ana, Solinis, Maria Angeles
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2014; Dove Press; Dove Medical Press
• Subjects: Lipids - chemistry; liposomes; Liposomes - administration & dosage; Liposomes - chemical synthesis; Medical research; Medicine, Experimental; Nanocapsules - administration & dosage; Nanocapsules - chemistry; Nanocapsules - ultrastructure; Nanomedicine; Nanoparticles; Nucleic Acid Amplification Techniques - methods; nucleic acid vaccines; Primates; Product development; Review; RNA; RNA replicon; self-amplifying RNA vaccine; solid lipid nanoparticles; Vaccines; Vaccines, DNA - administration & dosage; Vaccines, DNA - chemical synthesis; nucleic acid vaccines; RNA replicon; liposomes; self-amplifying RNA vaccine; solid lipid nanoparticles
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S39810

Self-amplifying RNA or RNA replicon is a form of nucleic acid-based vaccine derived from either positive-strand or negative-strand RNA viruses. The gene sequences encoding structural proteins in these RNA viruses are replaced by mRNA encoding antigens of interest as well as by RNA polymerase for replication and transcription. This kind of vaccine has been successfully assayed with many different antigens as vaccines candidates, and has been shown to be potent in several animal species, including mice, nonhuman primates, and humans. A key challenge to realizing the broad potential of self-amplifying vaccines is the need for safe and effective delivery methods. Ideally, an RNA nanocarrier should provide protection from blood nucleases and extended blood circulation, which ultimately would increase the possibility of reaching the target tissue. The delivery system must then be internalized by the target cell and, upon receptor-mediated endocytosis, must be able to escape from the endosomal compartment into the cell cytoplasm, where the RNA machinery is located, while avoiding degradation by lysosomal enzymes. Further, delivery systems for systemic administration ought to be well tolerated upon administration. They should be safe, enabling the multiadministration treatment modalities required for improved clinical outcomes and, from a developmental point of view, production of large batches with reproducible specifications is also desirable. In this review, the concept of self-amplifying RNA vaccines and the most promising lipid-based delivery systems are discussed.